ArticleJournal of animal science and biotechnology2025
Dietary xylooligosaccharides modulate oxidative stress and pathogen resistance in growing rabbits.
Article in Journal of animal science and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeted Preparation of Low-Degree Polymerization Xylooligosaccharides From Lignocellulosic Biomass: Advances, Structure-Activity Relationships, and Applications.Journal of food science · 2026Review
- Dietary semen cuscuta improves laying performance by stabilizing mitochondria-associated membranes (MAMs) and inhibiting granulosa cell apoptosis in laying hens.Poultry science · 2026Article
- Correction: Dietary xylooligosaccharides modulate oxidative stress and pathogen resistance in growing rabbits.Journal of animal science and biotechnology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgroundGiven the high incidence of gastrointestinal disorders in intensive rabbit production, we assessed the effects of graded levels of xylooligosaccharides (XOS) on growth performance, nutrient digestibility and intestinal health in growing rabbits.
methodsThe 35-day-old weaned rabbits (889.41 ± 0.41 g) were randomly assigned to five dietary treatments (0, 0.2, 0.3, 0.4 or 0.5 g/kg XOS) and the trial lasted for 35 d.
resultsThe results revealed that linear trend responses of body weight (BW) to XOS on d 21 and 35 (P ≤ 0.05). During d 1-21, 0.2 g/kg XOS increased average daily feed intake (ADFI) while 0.5 g/kg improved feed conversion ratio (FCR) significantly (P ≤ 0.05). Weight gain rate (WGR) showed a linear trend, while FCR showed a quadratic response (P ≤ 0.05). Throughout the 35-d trial, 0.2 and 0.3 g/kg XOS enhanced ADFI, and 0.4 g/kg XOS improved FCR significantly, average daily gain (ADG) demonstrated linear dose-responsiveness, while WGR and FCR showed quadratic trends (P ≤ 0.05). Notably, 0.2 g/kg XOS elevated serum glutathione peroxidase (GSH-Px) activity and ileal secretory immunoglobulin A (sIgA) levels. Furthermore, 0.3, 0.4 and 0.5 g/kg XOS reduced jejunal malonaldehyde (MDA) content, 0.4 g/kg XOS decreased serum MDA, and 0.5 g/kg XOS elevated serum immunoglobulin M (IgM) significantly (P ≤ 0.05). 0.2, 0.4, 0.5 g/kg XOS improved the digestibility of crude fiber (CF), 0.2 and 0.4 g/kg XOS increased acid detergent fiber (ADF), and neutral detergent fiber (NDF) also increased among all treatments, although 0.5 g/kg XOS reduced cellulase activity significantly (P ≤ 0.05). Furthermore, graded levels of XOS significantly changed the relative abundance of specific bacteria, and 0.4 and 0.5 g/kg XOS enhanced the content of valeric acid significantly (P ≤ 0.05).
conclusionsIn conclusion, dietary supplementation of XOS serves as an effective nutritional strategy to optimize bacterial community in the cecum, improve fiber digestion and valeric acid production, while enhances resistance to intestinal pathogen infection and oxidative stress in rabbit production.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.